Clinical Trial Update: Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy [Phase 1]

View source ↗

Summary

Mabylon AG's investigational therapy MY006 is in Phase 1 to evaluate safety, pharmacokinetics, and pharmacodynamics in healthy volunteers and patients with pean…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• MY006

Snippet

Sponsor: Mabylon AG | Conditions: Peanut Allergies | Phase 1 | Status: RECRUITING